TY - JOUR T1 - Diagnosis of celiac disease in clinical practice: Present and future JO - Anales de Pediatría (English Edition) T2 - AU - Crehuá-Gaudiza,Elena AU - Barrés Fernández,Ana AU - Jovaní Casano,Carmen AU - Latorre Tejerina,María AU - Largo Blanco,Ester María AU - Moreno Ruiz,María Antonia AU - Berghezan Suárez,Alicia AU - García-Peris,Mónica AU - Gil Piquer,Raquel AU - Coret Sinisterra,Alicia AU - Martínez-Barona,Sandra AU - Salido-Capilla,Cristina AU - Requena Fernández,María Ángeles AU - Arcos-Machancoses,Jose Vicente AU - Martínez-Costa,Cecilia SN - 23412879 M3 - 10.1016/j.anpede.2020.07.012 DO - 10.1016/j.anpede.2020.07.012 UR - https://www.analesdepediatria.org/en-diagnosis-celiac-disease-in-clinical-articulo-S234128792100020X AB - IntroductionEuropean guidelines for the diagnosis of celiac disease (CD) have been updated in 2020. The primary objective was to review the compliance with the diagnostic criteria for CD, according to ESPGHAN 2012. Secondarily, to describe the clinical characteristics of the patients and to assess the changes that would be implied by the application of the new 2020 criteria. Patients and methodsRetrospective multicenter study in which 10 centers participated. Patients from 0 to 16 years old with a new diagnosis of CD in 2018–2019 were included. Clinical, serological variables and the performance of intestinal biopsy (IB) were collected. Results163 patients were included (57% female) with a median age of 7.6 years (SD 4.4). The form of presentation was: 47.8% classical, 30.7% no classical and 21.5% asymptomatic, with differences depending on age. Total IgA and anti-transglutaminase IgA antibodies were performed in all centers as the first diagnostic step. IgA anti-endomysial antibodies (EMA) were performed in 80%, and HLA haplotype in 95%. Of the total, 78 cases (47.9%) met criteria for not performing intestinal biopsy (IB). IB was indicated in the remaining 85 patients, but was not performed in 29 cases (17.8%). The performance of IB was lower in the secondary hospitals than in the tertiary ones (p < 0.05).If we applied the ESPGHAN 2020 criteria, we would disregard the HLA study, and 21 more patients would not have required IB (going from 47.9% to 60.7% of the total). ConclusionsDiscrepancies are observed in the application of the ESPGHAN 2012 diagnostic criteria due to the different accessibility to EMA and endoscopic IB in secondary centers. With the ESPGHAN-2020 criteria, around 60% of patients will be able to be diagnosed without IB, provided that the determination of EMA is ensured. ER -